Research & Evidence
For the reader who discounts marketing language on sight and wants the line drawn without blur: what is published, what we measure on every batch, and what is still on the validation roadmap.
DLS in hand · DLVO stated as design principle · morphology imaging on the roadmap
This page is for the reader who discounts marketing language on sight and wants to see exactly what is measured, what is published, and what is still a target rather than a result. Good instinct. When you formulate on a modern architecture like NanoBase™, you are already working outside the logic of a single-balance-number HLB emulsion, and a fair reader will want to know precisely what backs that up. This page draws the line without blur: what is published, what we measure ourselves on every batch, and what is still on the validation roadmap. Unfamiliar terms are defined in our glossary.
NanoBase™ is an engineered, DLS-characterized tri-domain architecture: a nanocolloidal domain, a nanoliposomal domain, and a nanomicellar domain, co-populated by design inside one pourable, lecithin-based chassis, held apart by a DLVO-based electrostatic wall, not by the single balance number a legacy HLB emulsion is built around. Pensive Beauty® manufactures the architecture. Brands and contract manufacturers build finished products on top of it; they do not make the chassis itself. NanoBase™ is not a tweak to an HLB base; it is a modern replacement of an HLB base. Because the architecture is a chassis rather than a finished formula, it is not itself “clinically tested” as sold; what can be evidenced is its design, its characterization, and its adoption, and those are what the rest of this page documents.
Evidence status
The honest map of what stands where. Anything marked “future” is a roadmap commitment, not data in hand.
| Evidence area | Status | Source |
|---|---|---|
| Design logic and architecture rationale | Published | Zenodo preprint, CC-BY, not peer-reviewed |
| Characterization and validation approach | Published | Zenodo preprint, CC-BY, not peer-reviewed |
| TDA Logic definition (Tri-Domain Architecture logic) | Published | Zenodo preprint, CC-BY, not peer-reviewed |
| Particle size and polydispersity index | In hand, every batch | In-house multi-angle DLS |
| Electrostatic stabilization (DLVO) | Design principle | Stated as a design principle, not a measured figure |
| Direct morphology imaging | Future | Suggested method: cryo-TEM or SAXS |
| Skin-surface behavior | Future | Suggested deposition methods, named in the preprint as future validation |
| Independent adoption | In progress | Medical Aesthetics Certificate Program, Eastern Virginia Career College, effective 2027 |
The open preprints
Three open-access preprints, hosted on Zenodo under a CC-BY license, are self-published and not yet peer-reviewed. They propose a design framework; they are not evidence of finished-product performance. Read the primary sources directly rather than relying on our summary of them.
- NanoBase™ design logic (technical note, February 2026), Zenodo, CC-BY.
- NanoBase™ characterization and validation (preprint, August 2026), Zenodo, CC-BY.
- TDA Logic: The Tri-Domain Placement Logic Succeeding 1940s HLB Logic in Nanoscale Cosmetic Formulation (Version 1.0, 2026), the preprint that defines TDA Logic, Zenodo, CC-BY.
One of these preprints names specific deposition methods explicitly as suggested future validation, not as results already in hand. Direct morphological imaging, for example cryo-TEM or SAXS, sits in the same category: named as a roadmap commitment, not as data we are publishing today.
Why this updates a convention, not a law
NanoBase™ does not contest thermodynamics, and no physical law is disproven anywhere in this architecture.
It is worth being exact about what NanoBase™ updates and what it leaves alone. What it overturns is a design convention. Griffin’s 1949 HLB system was built to pick a single emulsifier balance number for a single expected stable morphology, and for seventy-plus years the field has treated any coexisting structure as a defect to be engineered out. That convention was never built to describe, let alone deliberately engineer, three coexisting colloidal domains at once, which is a large part of why so much “nano” language on the shelf today describes a single carrier type, judged against a framework that only ever expected one domain to exist. NanoBase™ does not patch that framework. It replaces it with a deliberately co-populated, electrostatically stabilized architecture in which a nanocolloidal domain, a nanoliposomal domain, and a nanomicellar domain coexist by design, characterized by multi-angle DLS. What the field has long framed as a defect (coexisting morphologies), NanoBase™ makes the architecture itself.
Two established results explain why this holds without contradicting anything underneath it. Nanoemulsions are kinetically, not thermodynamically, stable: their longevity comes from an engineered energy barrier, not from settling into the lowest-energy state (McClements, 2012), and that same activation barrier governs how long a kinetically stable system actually persists (Gupta, Eral & Hatton, 2016). NanoBase™ lives inside that same paradigm. Its electrostatic wall, a DLVO-based design principle, is the mechanism by which the tri-domain population is kept apart and prevented from coalescing into one, stated here as design logic, not as a measured stability figure. Separately, the classical packing-parameter picture maps one amphiphile to one preferred equilibrium morphology (Israelachvili, Mitchell & Ninham, 1976), which is the theoretical root of why a single-balance-number system is expected to settle into a single structure. The instinct to treat coexisting morphologies as a loss of control is not unique to cosmetics either: the polymer self-assembly literature documents the same reflex (Doncom et al., 2017), a different field entirely and not a study of NanoBase™ chemistry, cited here only to show how widely that instinct is shared.
We are precise with our verbs for a reason. We say the three domains are engineered and DLS-characterized. We do not say we have proven three coexisting morphologies: DLS reports a size distribution, not an image, and direct morphological confirmation is a future validation step, not data we hold today. For the full mechanism, see the architecture; for the direct comparison against legacy failure modes, see NanoBase™ vs HLB; for the doctrine behind the shift, see TDA Logic.
What DLS shows
Dynamic light scattering (DLS) is the one characterization assay Pensive Beauty® runs, and we run it on every batch, reading the architecture with multi-angle DLS. DLS reports an intensity-weighted hydrodynamic size distribution; it does not image structure or morphology directly. The design target is ~185 nm. A tri-domain design, with three populations designed to coexist, is expected to read as a broader, deliberately multimodal distribution rather than a narrow, single-population one. We do not describe the system as tightly uniform, because a multi-domain architecture is not meant to be, and a narrower number would misrepresent it.
What we deliberately do not publish matters just as much. The DLVO electrostatic wall is stated as a design principle, never as a measured stability confirmation. The multimodal size signature from DLS is what we actually measure, so it is what we actually report, nothing more.
What is still on the roadmap
Because DLS reports size and not structure, the assays that would confirm morphology directly, or test how a finished formula behaves on skin, are for us today suggested future methods, not data in hand. That list includes direct morphological imaging by cryo-TEM or SAXS and deposition studies on finished formulas. Naming a method here is a roadmap commitment, not a result we are claiming.
The nearer-term data path runs through the finished formula rather than the chassis alone. NanoBase™ is an architecture; a brand builds its actual product on top of it, and that finished product, not the chassis by itself, is what gets tested against its own claims. Third-party testing of a brand’s finished formula is the defensible route to on-skin data, and we will share such results as they become available. We are not putting a date on that.
On delivery specifically, NanoBase™ is a leave-on cosmetic raw material for intact skin and we make no claim about movement across the skin barrier; on-skin performance of a finished product is tested by the brand that builds it, not by us. We make no deposition or comparative-delivery claim for NanoBase™ until a study on finished formulas is published with its method.
An independent adoption signal
NanoBase™ has been included in the Medical Aesthetics Certificate Program curriculum at Eastern Virginia Career College, effective 2027. The educator endorsement behind that inclusion is offered in a personal capacity, not on behalf of the college or any accrediting board. We state the inclusion as an adoption fact, never as a scientific-priority claim.
Speaking in that personal capacity, the educator characterized the tri-domain architecture as a material advancement over legacy emulsion systems, and spoke to its scientific merit, technical depth, and educational value. We present that as informed professional opinion, not as clinical or performance data.
What we claim, and what we do not
What we claim
- NanoBase™ is an engineered, DLS-characterized tri-domain architecture: a nanocolloidal domain, a nanoliposomal domain, and a nanomicellar domain, co-populated by design inside one lecithin-based chassis.
- We run multi-angle DLS on every batch against a ~185 nm design target; a tri-domain design is expected to read as a wider, multimodal distribution.
- The architecture is held apart by a DLVO-based electrostatic wall, stated as a design principle, not a measured stability figure we are publishing.
- The system is kinetically stable within established colloid physics. It updates a design convention inherited from 1949 HLB emulsification; it does not contest thermodynamics, and no physical law is disproven.
- Two open-access Zenodo preprints document the design logic and characterization approach, and the architecture has been incorporated into an accredited medical-aesthetics certificate program, effective 2027.
- The architecture is built from INCI-listed, cosmetic-grade materials for leave-on use on intact skin.
What we do not claim
- We make no claim about movement across the skin barrier, and a finished product’s on-skin performance is tested by the brand that builds it, not by us.
- We do not describe the size distribution as tightly uniform.
- We have not imaged the three domains directly. DLS reports size, not structure; structural imaging and deposition studies are named as future validation, not current data.
- We do not present the preprints as proof of finished-product performance, and we make no disease, drug, or structure-function claim of any kind; this is a cosmetic material for leave-on use on intact skin.
See the characterization for yourself.
Approved brands, formulators, and buyers can request our full technical documentation package, including representative DLS characterization, or a sample of the architecture to evaluate directly.